AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31748948 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional farming practices in wolfberry production
Number of subjects: 52
Study 31748948 — intervention group
Group type: EXPERIMENTAL
Intervention: Electricity consumption for irrigation
Number of subjects: 52
Study 31748948 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen (N) fertilizer application
Number of subjects: 52
Study 31748948 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall GWP in wolfberry planting system
Number of subjects: 52
Study 31748948 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonrenewable energy use
Number of subjects: 52
Study 29654929 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health workers (CHWs) assisting patients with hypertension, using video narratives from patients who have controlled their BP through diet, exercise, and medication adherence. Participants met with CHWs 5 times (twice in person and three times telephonically).
Number of subjects: 0
Study 29654929 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (DI) group, receiving the intervention 4 to 6 months later.
Number of subjects: 0
Study 27172803 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 model (3D model without parenchyma)
Number of subjects: 92
Study 27172803 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 model (3D model with transparent parenchyma)
Number of subjects: 92
Study 27172803 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 3 model (3D model with segmental partitions)
Number of subjects: 92
Study 27172803 — intervention group
Group type: COMPARATOR
Intervention: Traditional Anatomic Atlas (TAA)
Number of subjects: 92
Study 24295218 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-instruction video (SIV)
Number of subjects: 45
Study 24295218 — intervention group
Group type: COMPARATOR
Intervention: Traditional face-to-face (FTF)
Number of subjects: 45
Study 22420423 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin monotherapy
Number of subjects: 71
Study 22420423 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin combined with 5-fluorouracil
Number of subjects: 71
Study 22420423 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin monotherapy
Number of subjects: 71
Study 22420423 — intervention group
Group type: COMPARATOR
Intervention: ATM levels in resistant tumors harboring TP53 or CHEK2 mutations
Number of subjects: 71
Study 20216467 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (25 g)
Number of subjects: 10
Study 20216467 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein (25 g)
Number of subjects: 10
Study 20216467 — intervention group
Group type: COMPARATOR
Intervention: Placebo (noncaloric)
Number of subjects: 10
Study 17496307 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural Killer (NK) cell count
Number of subjects: 140
Study 17496307 — intervention group
Group type: EXPERIMENTAL
Intervention: aaIPI 3
Number of subjects: 140
Study 17496307 — intervention group
Group type: EXPERIMENTAL
Intervention: NK cell count
Number of subjects: 140
Study 15774702 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (treadmill walking at 70% peak oxygen consumption, 400 kcal)
Number of subjects: 25
Study 12417603 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 500
Study 12417603 — intervention group
Group type: COMPARATOR
Intervention: Spleen preservation
Number of subjects: 500
Study 7552531 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral groin incision (Group A)
Number of subjects: 24
Study 7552531 — intervention group
Group type: COMPARATOR
Intervention: Direct incision over the femoral vessels (Group B)
Number of subjects: 24
Study 7552531 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with lymphatic obstruction (n = 8)
Number of subjects: 24
Study 7552531 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with no lymphatic lesions
Number of subjects: 24
Study 7552531 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with lymphatic obstruction
Number of subjects: 24
Study 2248076 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (100‐350 mg daily)
Number of subjects: 40
Study 2248076 — intervention group
Group type: COMPARATOR
Intervention: Tranylcypromine (10‐30 mg daily)
Number of subjects: 40
Study 2248076 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 40
Study 2248076 — intervention group
Group type: COMPARATOR
Intervention: Tranylcypromine
Number of subjects: 40
Study 6775209 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (350 mg per tablet, 2 tablets)
Number of subjects: 12
Study 6775209 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture (75 mg theophylline, 112.5 mg diprophylline, 112.5 mg proxyphylline per tablet, 2 tablets)
Number of subjects: 12
Study 6775209 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 12
Study 6775209 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture
Number of subjects: 12
Study 6871070 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular coffee (8 cups/day for 4 weeks, 504 mg caffeine)
Number of subjects: 8
Study 6871070 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee (8 cups/day for 4 weeks)
Number of subjects: 8
Study 6871070 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular coffee (8 cups/day for 4 weeks)
Number of subjects: 8
Study 31114694 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 196
Study 31114694 — intervention group
Group type: COMPARATOR
Intervention: iGlar
Number of subjects: 196
Study 31114694 — intervention group
Group type: COMPARATOR
Intervention: lixisenatide
Number of subjects: 196
Study 29866129 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g fat (Calogen®) per kg body weight orally
Number of subjects: 26
Study 29866129 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 26
Study 26751791 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural dexmedetomidine (3 ml loading dose at 0.5 μg kg(‐1) and continuous 80 μg in 150 ml levobupivacaine at 3 ml h(‐1) for two days)
Number of subjects: 74
Study 26751791 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine (3 ml loading dose at 0.03 mg kg(‐1) and continuous 4.5 mg in 150 ml levobupivacaine at 3 ml h(‐1) for two days)
Number of subjects: 74
Study 23976770 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable regimen (up to every 8 hours aspirations)
Number of subjects: 357
Study 23976770 — intervention group
Group type: COMPARATOR
Intervention: Control (every 4 hours aspirations)
Number of subjects: 357
Study 22274317 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history (FH) recorded in case notes
Number of subjects: 114
Study 22274317 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history recorded as not significant
Number of subjects: 114
Study 22274317 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufficient family history records
Number of subjects: 114
Study 22274317 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant family history meeting criteria for specialist genetics referral
Number of subjects: 114
Study 19179905 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 0
Study 19179905 — intervention group
Group type: EXPERIMENTAL
Intervention: N-telopeptide (marker of bone resorption)
Number of subjects: 0
Study 17597633 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese children with OSA
Number of subjects: 52
Study 17597633 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight children with OSA
Number of subjects: 52
Study 16310685 — intervention group
Group type: EXPERIMENTAL
Intervention: Original polypropylene mesh
Number of subjects: 184
Study 16310685 — intervention group
Group type: COMPARATOR
Intervention: Resterilized polypropylene mesh
Number of subjects: 184
Study 12215131 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (open carpal tunnel release)
Number of subjects: 176
Study 12215131 — intervention group
Group type: COMPARATOR
Intervention: Splinting (wrist splinting during the night for at least 6 weeks)
Number of subjects: 176
Study 10325486 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% adapalene gel
Number of subjects: 25
Study 10325486 — intervention group
Group type: COMPARATOR
Intervention: 0.05% tretinoin gel
Number of subjects: 25
Study 7782114 — intervention group
Group type: COMPARATOR
Intervention: Pentamidine aerosol (300 mg)
Number of subjects: 52
Study 7782114 — intervention group
Group type: COMPARATOR
Intervention: Pentamidine aerosol + Roxithromycin (300 mg t.i.d.)
Number of subjects: 52
Study 7782114 — intervention group
Group type: COMPARATOR
Intervention: Roxithromycin (300 mg t.i.d.)
Number of subjects: 52
Study 2031796 — intervention group
Group type: EXPERIMENTAL
Intervention: iopromide 300 (Ultravist)
Number of subjects: 446
Study 2031796 — intervention group
Group type: COMPARATOR
Intervention: iohexol 300 (Omnipaque)
Number of subjects: 446
Study 6781659 — intervention group
Group type: EXPERIMENTAL
Intervention: Photochemotherapy maintenance treatment once a week
Number of subjects: 0
Study 6781659 — intervention group
Group type: EXPERIMENTAL
Intervention: Photochemotherapy maintenance treatment once every three weeks
Number of subjects: 0
Study 6781659 — intervention group
Group type: COMPARATOR
Intervention: Ingram dithranol regimen
Number of subjects: 0
Study 6781659 — intervention group
Group type: COMPARATOR
Intervention: No maintenance treatment
Number of subjects: 0
Study 6781659 — intervention group
Group type: COMPARATOR
Intervention: Intermittent clearing courses
Number of subjects: 0
Study 6781659 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular maintenance treatment
Number of subjects: 0
Study 6781659 — intervention group
Group type: COMPARATOR
Intervention: No regular maintenance treatment
Number of subjects: 0
Study 29660107 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning landscape (LL)
Number of subjects: 6
Study 29660107 — intervention group
Group type: EXPERIMENTAL
Intervention: Curriculum intervention
Number of subjects: 6
Study 29660107 — intervention group
Group type: COMPARATOR
Intervention: Non-learning landscape (non-LL)
Number of subjects: 6
Study 29660107 — intervention group
Group type: COMPARATOR
Intervention: No curriculum intervention
Number of subjects: 6
Study 27940571 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT) plus Treatment as Usual (TAU)
Number of subjects: 94
Study 27940571 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 94
Study 25424715 — intervention group
Group type: EXPERIMENTAL
Intervention: GRM-derived SNP-based heritability estimates for GGT
Number of subjects: 5421
Study 25424715 — intervention group
Group type: EXPERIMENTAL
Intervention: GRM-derived SNP-based heritability estimates for AST
Number of subjects: 5421
Study 25424715 — intervention group
Group type: EXPERIMENTAL
Intervention: GRM-derived SNP-based heritability estimates for ALT
Number of subjects: 5421
Study 25424715 — intervention group
Group type: EXPERIMENTAL
Intervention: DE method for all liver enzymes
Number of subjects: 5421
Study 25424715 — intervention group
Group type: EXPERIMENTAL
Intervention: DE method applied to meta-analysis results for GGT
Number of subjects: 5421
Study 25424715 — intervention group
Group type: EXPERIMENTAL
Intervention: DE method applied to meta-analysis results for ALT
Number of subjects: 5421
Study 23403276 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed incentives ($75 loss per day for smoking, initial endowment=$375)
Number of subjects: 0
Study 23403276 — intervention group
Group type: COMPARATOR
Intervention: Gain-framed incentives ($75 gain per day for abstinence)
Number of subjects: 0
Study 23403276 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed incentives
Number of subjects: 0
Study 21861971 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% reduction in retinal thickness
Number of subjects: 101
Study 21861971 — intervention group
Group type: COMPARATOR
Intervention: No 20% reduction in retinal thickness
Number of subjects: 101
Study 18542850 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGBP)
Number of subjects: 21
Study 18542850 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 17384434 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 984
Study 15170977 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX 4
Number of subjects: 0
Study 15170977 — intervention group
Group type: EXPERIMENTAL
Intervention: IFL regimen
Number of subjects: 0
Study 15170977 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU and leucovorin (FL)
Number of subjects: 0
Study 15170977 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IFL and bevacizumab
Number of subjects: 0
Study 15170977 — intervention group
Group type: EXPERIMENTAL
Intervention: de Gramont regimen
Number of subjects: 0
Study 15170977 — intervention group
Group type: COMPARATOR
Intervention: CPT‐11 and oxaliplatin (IROX)
Number of subjects: 0
Study 12752559 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-hypotensive haemorrhage (5.6 +/- 1.2 ml kg-1 body weight)
Number of subjects: 30
Study 12752559 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-hypotensive haemorrhage
Number of subjects: 30
Study 9916067 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal antigen
Number of subjects: 0
Study 9916067 — intervention group
Group type: COMPARATOR
Intervention: Antigen only
Number of subjects: 0
Study 9916067 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 7675920 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressful laboratory task (N = 40)
Number of subjects: 70
Study 7675920 — intervention group
Group type: COMPARATOR
Intervention: Rest condition (N = 30)
Number of subjects: 70
Study 2292547 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 51
Study 2292547 — intervention group
Group type: COMPARATOR
Intervention: Intra-peritoneal vancomycin/gentamicin
Number of subjects: 51
Study 7292264 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic oophorectomy
Number of subjects: 359
Study 7292264 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 359
Study 30044438 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond snack (56.7 g/day; 364 kcal; n = 38)
Number of subjects: 73
Study 30044438 — intervention group
Group type: COMPARATOR
Intervention: Graham cracker control (77.5 g/day; 338 kcal/d; n = 35)
Number of subjects: 73
Study 26922457 — intervention group
Group type: EXPERIMENTAL
Intervention: Redesigned Rx labels (n = 90)
Number of subjects: 118
Study 26922457 — intervention group
Group type: EXPERIMENTAL
Intervention: Redesigned Rx labels (n = 48) after educational intervention
Number of subjects: 118
Study 26922457 — intervention group
Group type: COMPARATOR
Intervention: Current Rx labels (n = 16) after educational intervention
Number of subjects: 118
Study 26922457 — intervention group
Group type: COMPARATOR
Intervention: Current Rx labels (n = 28)
Number of subjects: 118
Study 24907871 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 80
Study 24907871 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 80
Study 24907871 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 80
Study 24907871 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 80
Study 22393219 — intervention group
Group type: EXPERIMENTAL
Intervention: MFG-adherence
Number of subjects: 174
Study 22393219 — intervention group
Group type: COMPARATOR
Intervention: MFG-standard
Number of subjects: 174
Study 22393219 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 174
Study 19889469 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multifactorial treatment (stepwise implementation of behavior modification, pharmacological therapy targeting hyperglycaemia, hypertension, dyslipidaemia, and proteinuria)
Number of subjects: 600
Study 19889469 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 600
Study 19079390 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary posterior capsulotomy (PPC)
Number of subjects: 114
Study 19079390 — intervention group
Group type: COMPARATOR
Intervention: No primary posterior capsulotomy (NPPC)
Number of subjects: 114
Study 19079390 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PPC and NPPC
Number of subjects: 114
Study 16268465 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral CVL
Number of subjects: 158
Study 16268465 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclavian CVL
Number of subjects: 158
Study 16268465 — intervention group
Group type: COMPARATOR
Intervention: Brachial CVL
Number of subjects: 158
Study 16268465 — intervention group
Group type: COMPARATOR
Intervention: Jugular CVL
Number of subjects: 158
Study 16268465 — intervention group
Group type: EXPERIMENTAL
Intervention: CVL type (peripherally inserted central catheters, untunneled CVL, tunneled exteriorized CVL, subcutaneous ports)
Number of subjects: 158
Study 16268465 — intervention group
Group type: EXPERIMENTAL
Intervention: CVL size (CVL diameter, number of CVL lumen)
Number of subjects: 158
Study 16268465 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of CVL placement (0-5 days, 6-20 days, 21-35 days, 36-50 days)
Number of subjects: 158
Study 12297918 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous prostaglandin E1 (PGE1), n = 18
Number of subjects: 44
Study 12297918 — intervention group
Group type: COMPARATOR
Intervention: No PGE1 treatment (PGE1(-) group), n = 26
Number of subjects: 44
Study 12297918 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-field lymph node dissection and reconstruction of the retrosternal route, n = 21
Number of subjects: 44
Study 12297918 — intervention group
Group type: COMPARATOR
Intervention: Two-field lymph-node dissection and reconstruction of the posterior mediastinal route, n = 23
Number of subjects: 44
Study 12297918 — intervention group
Group type: EXPERIMENTAL
Intervention: Leakage(+) group, n = 5
Number of subjects: 44
Study 12297918 — intervention group
Group type: COMPARATOR
Intervention: Leakage(?) group, n = 39
Number of subjects: 44
Study 11074998 — intervention group
Group type: EXPERIMENTAL
Intervention: Graftskin plus compression therapy
Number of subjects: 240
Study 11074998 — intervention group
Group type: COMPARATOR
Intervention: Compression therapy alone (active control)
Number of subjects: 240
Study 8777102 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion (240 kJ h‐1, infused over 1‐2 h before anaesthesia)
Number of subjects: 24
Study 8777102 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 24
Study 2000818 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg beta-carotene/d orally
Number of subjects: 61
Study 2000818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 6653137 — intervention group
Group type: EXPERIMENTAL
Intervention: Pholcolix
Number of subjects: 217
Study 6653137 — intervention group
Group type: COMPARATOR
Intervention: Actifed Compound
Number of subjects: 217
Study 31651407 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-coaching smartphone app (Glycoleap, Holmusk, Singapore) for 8 weeks
Number of subjects: 30
Study 31651407 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard pregnancy dietary orientation)
Number of subjects: 30
Study 31651407 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-coaching smartphone app (Glycoleap, Holmusk, Singapore)
Number of subjects: 30
Study 29142294 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH 10 μg
Number of subjects: 67
Study 29142294 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH 50 μg
Number of subjects: 67
Study 29142294 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH 100 μg
Number of subjects: 67
Study 29142294 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH (all doses)
Number of subjects: 67
Study 27084861 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut oil pulling (10 ml for 10 minutes)
Number of subjects: 60
Study 27084861 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash (5 ml for 1 minute)
Number of subjects: 60
Study 27084861 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (5 ml for 1 minute)
Number of subjects: 60
Study 25458229 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Based Learning (PBL)
Number of subjects: 70
Study 25458229 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 70
Study 23006479 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ascorbic acid intravenously before exercise
Number of subjects: 0
Study 23006479 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity (0.5 kg) rhythmic plantar flexion
Number of subjects: 0
Study 23006479 — intervention group
Group type: COMPARATOR
Intervention: Electrically evoked exercise
Number of subjects: 0
Study 20339913 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg/day
Number of subjects: 700
Study 20339913 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine 1,250 mg/m2 (1,000 mg/m2 in patients >65 years) BID on days 1-14 q3w
Number of subjects: 700
Study 17276006 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-point transition question (TQ2)
Number of subjects: 233
Study 17276006 — intervention group
Group type: COMPARATOR
Intervention: 7-point transition question (TQ1)
Number of subjects: 233
Study 17276006 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective transition questions (TQ1 and TQ2)
Number of subjects: 233
Study 15907777 — intervention group
Group type: EXPERIMENTAL
Intervention: Active dose of alcohol (0.65 g/kg)
Number of subjects: 28
Study 15907777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 11821453 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab 4 mg/kg loading dose, followed by 2 mg/kg weekly
Number of subjects: 114
Study 11821453 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab 8 mg/kg loading dose, followed by 4 mg/kg weekly
Number of subjects: 114
Study 11821453 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (both dosages)
Number of subjects: 114
Study 10351855 — intervention group
Group type: EXPERIMENTAL
Intervention: STARS for Families Program (alcohol reduction program with standardized health consultations and mailed follow‐up information)
Number of subjects: 650
Study 10351855 — intervention group
Group type: COMPARATOR
Intervention: Minimum information (control group)
Number of subjects: 650